GLENMARK THERAPEUTICS
DEAD

Serial Number

77401648

Owner

GLENMARK THERAPEUTICS INC., USA

Filing Date

Feb 20, 2008

Add to watchlist:

No watchlists yet
View on USPTO

GLENMARK THERAPEUTICS Trademark

Serial Number: 77401648

GLENMARK THERAPEUTICS is a trademark filed by GLENMARK THERAPEUTICS INC., USA on February 20, 2008. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

GLENMARK THERAPEUTICS INC., USA (40 trademarks)

MAHWAH, NJ 07430

Entity Type: 03

GLENMARK PHARMACEUTICALS INC., USA (38 trademarks)

750 CORPORATE DR.
MAHWAH, NJ 07430

Entity Type: 03

Trademark Details

Filing Date

February 20, 2008

Registration Date

Not Registered

Published for Opposition

January 27, 2009

Goods & Services

Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Preparation for the relief of pain

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
May 23, 2011 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 23, 2011 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 28, 2010 EXRA
SOU EXTENSION 3 GRANTED
Oct 27, 2010 EX3G
SOU EXTENSION RECEIVED WITH TEAS PETITION
Oct 26, 2010 TPEX
PETITION TO REVIVE-GRANTED
Oct 26, 2010 PETG
TEAS PETITION TO REVIVE RECEIVED
Oct 26, 2010 PROA
SOU EXTENSION 3 FILED
Oct 21, 2010 EXT3
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 21, 2010 EXRA
SOU EXTENSION 2 GRANTED
May 20, 2010 EX2G
SOU EXTENSION RECEIVED WITH TEAS PETITION
May 19, 2010 TPEX
PETITION TO REVIVE-GRANTED
May 19, 2010 PETG
TEAS PETITION TO REVIVE RECEIVED
May 19, 2010 PROA
SOU EXTENSION 2 FILED
Apr 21, 2010 EXT2
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 3, 2010 ASGN
SOU EXTENSION 1 GRANTED
Mar 2, 2010 EX1G
PETITION GRANTED - EXTENSION REQUEST FILED
Mar 1, 2010 PGEX
INCOMPLETE PETITION NOTICE MAILED
Feb 3, 2010 PINM
ASSIGNED TO PETITION STAFF
Feb 2, 2010 APET
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 1, 2010 AITU
PETITION TO REVIVE-RECEIVED
Dec 1, 2009 PETR
SOU EXTENSION RECEIVED WITH TEAS PETITION
Dec 1, 2009 TPEX
PETITION TO REVIVE-GRANTED
Dec 1, 2009 PETG
TEAS PETITION TO REVIVE RECEIVED
Dec 1, 2009 PROA
ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Nov 23, 2009 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 23, 2009 ABN6
SOU EXTENSION 1 FILED
Oct 21, 2009 EXT1
NOA MAILED - SOU REQUIRED FROM APPLICANT
Apr 21, 2009 NOAM
PUBLISHED FOR OPPOSITION
Jan 27, 2009 PUBO
NOTICE OF PUBLICATION
Jan 7, 2009 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 22, 2008 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 16, 2008 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 15, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 15, 2008 CRFA
ASSIGNED TO LIE
Dec 15, 2008 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 1, 2008 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 2, 2008 GNRN
NON-FINAL ACTION E-MAILED
Jun 2, 2008 GNRT
NON-FINAL ACTION WRITTEN
Jun 2, 2008 CNRT
ASSIGNED TO EXAMINER
Jun 2, 2008 DOCK
NOTICE OF PSEUDO MARK MAILED
Feb 27, 2008 MPMK
NEW APPLICATION ENTERED
Feb 26, 2008 NWAP